Dr Reddy's Laboratories will be making six scientific presentations on the findings of its discovery research at the 63rd Scientific Sessions of the American Diabetes Association being held between June 13 and June 17, at New Orleans, US.
The abstracts being presented will highlight the progress of Dr Reddy's discovery programme. It will include a demonstration of the pre-clinical efficacy and safety of the company's pipeline compounds in developing treatment for Type-2 diabetes.
The company will also give demonstrations on the discovery of potential new diagnostic markers for the onset of Type-2 diabetes, and mechanisms of accelerated cardiovascular disease in diabetics, the company said in a release.
This is the third successive year that Dr Reddy's scientists are presenting their research findings at the ADA.
The annual ADA meetings are the premier platform for presentations on diabetes-related research. The abstracts are peer-reviewed before being accepted for presentation, the release added.
The company also announced that it would hold its scientific advisory board meeting in New Orleans on June 14, 2003.
The board, consisting of international scientific opinion leaders, will review the progress of the company's discovery research programme in the areas of diabetes, cardiovascular diseases and inflammation.
This will be followed by a clinical consortium meeting in Atlanta on June 18. The consortium will consist of a panel of international experts, who will review the progress and strategy for the clinical development of the company's anti-cancer molecules.
© 2025 Rediff.com -